Disease · MONDO_0021100
breast neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. breast neoplasm. Diseases, record MONDO_0021100. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021100
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
BREAST NEOPL, Breast Neoplasms, Breast Tumors, Human Mammary Neoplasm, Human Mammary Neoplasms, Mammary Neoplasm, Human, Mammary Neoplasms, Human, NEOPL BREAST, Neoplasm, Human Mammary, Neoplasms, Breast, Neoplasms, Human Mammary, Tumor, Breast, Tumors, Breast, breast neoplasm (disease), breast tumor, breast tumour, neoplasm of breast, neoplasm of the breast, neoplasm, breast, tumor of breast, tumor of the breast, tumour of breast, tumour of the breast
- Open Targets
- Highest stage of its drugs
- Approval, for 34 of its 46 drugs, from EMA Human Drugs and FDA
- Open Targets
Drugs46
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DOCETAXEL | CHEMBL3545252 | Small molecule | Approval | EMA Human Drugs | 14 | 3 | 3 | Drugs and targets |
| LAPATINIB | CHEMBL554 | Small molecule | Approval | EMA Human Drugs | 3 | 2 | 2 | Drugs and targets |
| TRASTUZUMAB | CHEMBL1201585 | Antibody | Approval | EMA Human Drugs | 14 | 1 | 1 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Approval | EMA Human Drugs | 6 | 1 | 1 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Approval | EMA Human Drugs | 5 | 1 | 1 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Approval | EMA Human Drugs | 12 | 0 | 0 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Approval | EMA Human Drugs | 5 | 0 | 0 | Drugs and targets |
| IBANDRONIC ACID | CHEMBL997 | Small molecule | Approval | EMA Human Drugs | 5 | 0 | 0 | Drugs and targets |
| ERIBULIN | CHEMBL1683590 | Small molecule | Approval | EMA Human Drugs | 3 | 0 | 0 | Drugs and targets |
| PERTUZUMAB | CHEMBL2007641 | Antibody | Approval | EMA Human Drugs | 3 | 0 | 0 | Drugs and targets |
1 to 10 of 46
See all 46 drugsTargets41
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 7 | Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor | Approval | https://conductscience.org/library/genes/2064 | Drugs and targets |
| ESR1 | Estrogen receptor | 7 | Estrogen receptor alpha antagonist; Estrogen receptor alpha degrader; Estrogen receptor alpha modulator; Estrogen receptor degrader; Estrogen receptor modulator | Approval | https://conductscience.org/library/genes/2099 | Drugs and targets |
| PARP1 | PARP 1, 2 and 3 | 4 | PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | Approval | https://conductscience.org/library/genes/142 | Drugs and targets |
| PARP2 | PARP 1, 2 and 3 | 4 | PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor | Approval | https://conductscience.org/library/genes/10038 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 4 | DNA topoisomerase I inhibitor | Approval | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Approval | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Approval | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 4 | Tubulin inhibitor | Approval | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 4 | Tubulin inhibitor | Approval | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 4 | Tubulin inhibitor | Approval | https://conductscience.org/library/genes/112714 | Drugs and targets |
1 to 10 of 41
See all 41 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00941330 | Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers | Phase 2 | 31 | 2017-04-10 | Breast Cancer | CYCLOPHOSPHAMIDE, DOCETAXEL, EXEMESTANE | Its record names the disease | ClinicalTrials.gov |
| NCT01973660 | PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | Phase 2 | 151 | Breast Cancer | LAPATINIB, LETROZOLE, PACLITAXEL, TAMOXIFEN, TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02314806 | Gentamicin Versus Clindamycin Versus Normal Saline Lavage in Axilla | Phase 3 | 51 | Breast Cancer | CLINDAMYCIN, GENTAMICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00669773 | Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient | Phase 2 | 49 | Breast Cancer | DOCETAXEL, DOXORUBICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01700504 | Effect of Gentamicin Lavage of the Axillary Surgical Bed After Lymph Node Dissection on Drainage Discharge Volume | Phase 3 | 40 | Axillary Drainage Volume After Lymph Node Dissection. | GENTAMICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06633601 | MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer | Phase 1 | 30 | Breast Cancer | PERFLUTREN | Its record names the disease | ClinicalTrials.gov | |
| NCT03911453 | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Early phase 1 | 20 | Breast Cancer | RUCAPARIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00919399 | Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | Phase 2 | 15 | Breast Neoplasms | EXEMESTANE, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT00617968 | GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer | Phase 2 | 5 | Breast Neoplasms | DOCETAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00343759 | Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy | Phase 2 | 0 | Breast Cancer | LAPATINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| A: Exemestane vs B: Docetaxel and Cytoxan: serious adverse events | 0 of 15 | 1 of 11 | 26 | NCT00941330 |
Source Trial comparisons
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021100
GET https://conductscience.org/api/diseases/v1/MONDO_0021100/drugs?page=2